FDMT - 4D Molecular Therapeutics Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
4D Molecular Therapeutics (FDMT) specializes in developing gene delivery systems for the treatment of vision pathologies and cardiology using a single core technology. The price history on GURU.Markets, where the EV/EBITDA ratio equals 0.00, links these developments to the production cycle in California sterile laboratories with autonomous power supplies. Business prospects are bolstered by high demand for drugs treating macular degeneration.
4DMT (FDMT) - metric breakdowns and financial figures
- share price and expert price forecast:
- market capitalization statistics:
- book value of equity indicators:
- issuer credit burden and liquidity indicators:
Total Debt to Capital 4D Molecular Therapeutics|FDMT - Long-Term Debt to Equity|Short-Term Debt to Equity 4DMT|FDMT - Company Aggregate Debts|Debts to Book Capitalization 4D Molecular Therapeutics, Inc.|FDMT - Company Long-Term Debt|Company Short-Term Loans and Borrowings 4D Molecular Therapeutics|Intermediate Coverage Ratio 4dmoleculartherapeutics.com
- earnings and valuation multiples indicators:
FDMT - Net Income|Future Net Profit 4D Molecular Therapeutics|FDMT - P/E Multiple|Future Price to Earnings Multiple 4dmoleculartherapeutics.com|FDMT - PEG Multiple|Company Value to EBITDA 4D Molecular Therapeutics, Inc.|FDMT - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year 4D Molecular Therapeutics|FDMT - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth 4dmoleculartherapeutics.com|FDMT - Earnings per share growth in current year|Net earnings per share change forecast for next year 4D Molecular Therapeutics
- total revenue and sales volume data:
Fundamental company analysis:4D Molecular Therapeutics FDMT
EV/EBITDA measures the total enterprise value, including net debt, relative to operating profit before depreciation and amortization. The formula is sensitive to debt load and capital expenditures, allowing for the determination of an asset's fair value. By analyzing the EV/EBITDA ratio of a company on the GURU.Markets platform, an investor identifies fundamental support levels. Strategic partnerships of 4D Molecular Therapeutics (FDMT) in gene therapy reduce operational risks, which directly stabilizes this metric.
Who 4D Molecular Therapeutics competes with
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tempus AI TEM|qiagen.com (QGEN) - Company Value to EBITDA|IONS: Enterprise Value to EBITDA Ratio|Enterprise Value to EBITDA Multiple Repligen (RGEN)|RNA (Avidity) - Enterprise Value to EBITDA Ratio|CRISPR Therapeutics AG - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization GeneDx Holdings|Enterprise Value to Operating Income Before Depreciation RARE (Ultragenyx)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Beam Therapeutics (BEAM)|Enterprise Value to Operating Income Before Depreciation Ratio SRPT|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Twist Bioscience Corp TWST|Total Company Value to Operating Income Before Depreciation Ratio 10x Genomics, Inc. (TXG)|Intellia Therapeutics - EV/EBITDA Multiple|STOK - EV/EBITDA Multiple|BLFS (biolifesolutions.com) - Enterprise Value to EBITDA Ratio|WVE - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio MAZE|Sionna Pharma - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple PRME|TSHA (Taysha Gene Therapies) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization uniQure QURE|MGTX: Enterprise Value to Operating Income Before Depreciation|REGENXBIO Inc - EV/EBITDA Multiple|Company Value to EBITDA Solid Corp|Ocugen (OCGN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Pacific Biosciences|Enterprise Value to EBITDA Ratio BNTC|Enterprise Value to EBITDA Ratio Design Therapeutics Inc (DSGN)|EV/EBITDA Multiple RCKT|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization LXEO (Lexeo)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization korrobio.com KRRO|Total Company Value to Operating Income Before Depreciation Ratio Editas Medicine, Inc. (EDIT)|SLN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio ProQR PRQR|CDXS: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Sangamo BioSciences SGMO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Nautilus Bio|MGX (Metagenomi, Inc.) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple DTIL|Generation Bio - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple BOLD (Boundless Bio Inc.)|Business Value to Operating Income Before Depreciation XCUR|Imunon Inc - EV/EBITDA Multiple|PHIO (phiopharma.com) - Enterprise Value to Operating Income Before Depreciation|MBIO (mustangbio.com) - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation RNAZ|BNGO (Bionano) - EV/EBITDA Multiple|EV/EBITDA Multiple Applied DNA Corp|EV/EBITDA Multiple BLUE|EV/EBITDA Multiple ImmunoPrecise Antibodies Ltd. (IPA)|EV/EBITDA Multiple OMGA (omegatherapeutics.com)|OMIC: Enterprise Value to Operating Income Before Depreciation|RGLS: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation SYRS (Syros Pharmaceuticals, Inc)|TBIO: EV/EBITDA Multiple|TRACON Pharmaceuticals (TCON) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Unity Biotechnology, Inc
